UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

PloS one, 2017-07, Vol.12 (7), p.e0179431

2017

Volltextzugriff (PDF)

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Nature communications, 2020-01, Vol.11 (1), p.661-11, Article 661

2020

Volltextzugriff (PDF)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Journal of clinical oncology, 2021-09, Vol.39 (26), p.2914-2925

2021

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

Journal of clinical oncology, 2010-06, Vol.28 (18), p.3015-3022

2010

Volltextzugriff (PDF)

Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol

Clinical cancer research, 2018-07, Vol.24 (14), p.3348-3357

2018

Volltextzugriff (PDF)

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study

The lancet oncology, 2013-11, Vol.14 (12), p.1216-1225

2013

Volltextzugriff (PDF)

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

Journal for immunotherapy of cancer, 2022-04, Vol.10 (4), p.e004419

2022

Volltextzugriff (PDF)

Discovery of a potent and selective Aurora kinase inhibitor

Bioorganic & medicinal chemistry, 2008-09, Vol.18 (17), p.4880-4884

2008

Volltextzugriff (PDF)

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules

Clinical cancer research, 2010-04, Vol.16 (7), p.2167-2175

2010

Volltextzugriff (PDF)

Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent

Drug metabolism and disposition, 2009-03, Vol.37 (3), p.594-601

2009

Volltextzugriff (PDF)

420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A256-A256

2020

Volltextzugriff (PDF)

Covalently Linked Heme in Cytochrome P4504A Fatty Acid Hydroxylases

The Journal of biological chemistry, 2001-04, Vol.276 (14), p.11339-11346

2001

Volltextzugriff (PDF)

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

Cancer discovery, 2019-06, Vol.9 (6), p.711-721

2019

Volltextzugriff (PDF)

Pharmacokinetics in Animals and Humans of a First-in-Class Peptide Deformylase Inhibitor

Antimicrobial Agents and Chemotherapy, 2004-12, Vol.48 (12), p.4835-4842

2004

Volltextzugriff (PDF)

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

Clinical cancer research, 2016-02, Vol.22 (3), p.680-690

2016

Volltextzugriff (PDF)

Autocatalytic Mechanism and Consequences of Covalent Heme Attachment in the Cytochrome P4504A Family

The Journal of biological chemistry, 2002-04, Vol.277 (15), p.12755-12761

2002

Volltextzugriff (PDF)

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models

Cancer chemotherapy and pharmacology, 2014-12, Vol.74 (6), p.1125-1137

2014

Volltextzugriff (PDF)

Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02

European urology, 2022-10, Vol.82 (4), p.365-373

2022

Volltextzugriff (PDF)

Abstract A95: NKTR-214, a novel CD122-biased immunostimulatory cytokine, does not cause hypotension in non-human primates despite greater cytokine exposure than achieved with high dose Interleukin-2 (HD-IL-2)

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A95-A95

2015

Volltextzugriff (PDF)

Abstract 1598: Single agent NKTR-214, a biased IL2 pathway agonist, increases immune cell infiltrates in brain tumors and prolongs survival in rodent (rattus) glioblastoma (GBM)

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1598-1598

2017

Volltextzugriff (PDF)

Abstract 1604: NKTR-214 synergizes with radiotherapy to drive tumor regression

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1604-1604

2017

Volltextzugriff (PDF)

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Breast cancer research and treatment, 2017-09, Vol.165 (2), p.329-341

2017

Volltextzugriff (PDF)

Abstract C209: Strong synergistic activity of NKTR-102-pegylated liposomal doxorubicin (PLD) combination therapy in a nonclinical model of platinum-resistant A2780 human ovarian cancer

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.C209-C209

2011

Volltextzugriff (PDF)

1 – 25 von 104

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(98)

Publikationsform

Sprache

Englisch
(101)
Japanisch
(8)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

Discovery of a potent and selective Aurora kinase inhibitor

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules

Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent

420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study

Covalently Linked Heme in Cytochrome P4504A Fatty Acid Hydroxylases

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Pharmacokinetics in Animals and Humans of a First-in-Class Peptide Deformylase Inhibitor

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

Autocatalytic Mechanism and Consequences of Covalent Heme Attachment in the Cytochrome P4504A Family

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models

Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02

Abstract A95: NKTR-214, a novel CD122-biased immunostimulatory cytokine, does not cause hypotension in non-human primates despite greater cytokine exposure than achieved with high dose Interleukin-2 (HD-IL-2)

Abstract 1598: Single agent NKTR-214, a biased IL2 pathway agonist, increases immune cell infiltrates in brain tumors and prolongs survival in rodent (rattus) glioblastoma (GBM)

Abstract 1604: NKTR-214 synergizes with radiotherapy to drive tumor regression

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Abstract C209: Strong synergistic activity of NKTR-102-pegylated liposomal doxorubicin (PLD) combination therapy in a nonclinical model of platinum-resistant A2780 human ovarian cancer

Suchergebnisse filtern